{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T01:53:21Z","timestamp":1789782801765,"version":"4.0.1"},"reference-count":103,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.3816\/clml.2010.n.053","type":"journal-article","created":{"date-parts":[[2010,8,14]],"date-time":"2010-08-14T06:11:22Z","timestamp":1281766282000},"page":"248-257","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Smoldering (Asymptomatic) Multiple Myeloma: Revisiting the Clinical Dilemma and Looking Into the Future"],"prefix":"10.3816","volume":"10","author":[{"given":"Adam J.","family":"Waxman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kuehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Balakumaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola","family":"Landgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.3816\/CLML.2010.n.053_bib1","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1038\/leu.2009.134","article-title":"Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic\/racial groups: support for genetic factors in pathogenesis","volume":"23","author":"Landgren","year":"2009","journal-title":"Leukemia"},{"key":"10.3816\/CLML.2010.n.053_bib2","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1002\/cncr.20652","article-title":"Incidence of multiple myeloma in Olmsted County, Minnesota: Trend over 6 decades","volume":"101","author":"Kyle","year":"2004","journal-title":"Cancer"},{"key":"10.3816\/CLML.2010.n.053_bib3","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJMoa01133202","article-title":"A long-term study of prognosis in monoclonal gammopathy of undetermined significance","volume":"346","author":"Kyle","year":"2002","journal-title":"N Engl J Med"},{"key":"10.3816\/CLML.2010.n.053_bib4","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMoa054494","article-title":"Prevalence of monoclonal gammopathy of undetermined significance","volume":"354","author":"Kyle","year":"2006","journal-title":"N Engl J Med"},{"key":"10.3816\/CLML.2010.n.053_bib5","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/j.1365-2141.2006.06235.x","article-title":"Monoclonal gammopathy of undetermined significance","volume":"134","author":"Kyle","year":"2006","journal-title":"Br J Haematol"},{"key":"10.3816\/CLML.2010.n.053_bib6","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.blre.2007.01.002","article-title":"Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma","volume":"21","author":"Rajkumar","year":"2007","journal-title":"Blood Rev"},{"key":"10.3816\/CLML.2010.n.053_bib7","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma","volume":"356","author":"Kyle","year":"2007","journal-title":"N Engl J Med"},{"key":"10.3816\/CLML.2010.n.053_bib8","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1182\/blood-2007-10-078022","article-title":"Multiple myeloma","volume":"111","author":"Kyle","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.053_bib9","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.053_bib10","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1200\/JCO.2006.09.0100","article-title":"Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003","volume":"25","author":"Kristinsson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.053_bib11","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.053_bib12","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1182\/blood-2008-12-195008","article-title":"A monoclonal gammopathy precedes multiple myeloma in most patients","volume":"113","author":"Weiss","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.053_bib13","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1056\/NEJM198006123022405","article-title":"Smoldering multiple myeloma","volume":"302","author":"Kyle","year":"1980","journal-title":"N Engl J Med"},{"key":"10.3816\/CLML.2010.n.053_bib14","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1001\/archinte.1988.00380090051014","article-title":"Prognosis of asymptomatic multiple myeloma","volume":"148","author":"Alexanian","year":"1988","journal-title":"Arch Intern Med"},{"key":"10.3816\/CLML.2010.n.053_bib15","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0002-9343(93)90120-E","article-title":"Risk of disease progression in asymptomatic multiple myeloma","volume":"94","author":"Dimopoulos","year":"1993","journal-title":"Am J Med"},{"key":"10.3816\/CLML.2010.n.053_bib16","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1365-2141.1994.tb04908.x","article-title":"Detection of peripheral blood plasma cells as a predictor of disease course in patients with smouldering multiple myeloma","volume":"87","author":"Witzig","year":"1994","journal-title":"Br J Haematol"},{"key":"10.3816\/CLML.2010.n.053_bib17","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s11864-000-0056-3","article-title":"Smoldering, asymptomatic stage I, and indolent myeloma","volume":"1","author":"Greipp","year":"2000","journal-title":"Curr Treat Options Oncol"},{"key":"10.3816\/CLML.2010.n.053_bib18","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1038\/sj.leu.2402183","article-title":"Thalidomide for previously untreated indolent or smoldering multiple myeloma","volume":"15","author":"Rajkumar","year":"2001","journal-title":"Leukemia"},{"key":"10.3816\/CLML.2010.n.053_bib19","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","article-title":"Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group","volume":"121","author":"International Myeloma Working Group","year":"2003","journal-title":"Br J Haematol"},{"key":"10.3816\/CLML.2010.n.053_bib20","doi-asserted-by":"crossref","first-page":"4762","DOI":"10.1182\/blood.V87.11.4762.bloodjournal87114762","article-title":"Quantifiable excess of bone resorption in monoclonal gammopathy is an early symptom of malignancy: a prospective study of 87 bone biopsies","volume":"87","author":"Bataille","year":"1996","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.053_bib21","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/j.1365-2141.2004.05092.x","article-title":"Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS)","volume":"126","author":"Politou","year":"2004","journal-title":"Br J Haematol"},{"key":"10.3816\/CLML.2010.n.053_bib22","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1359\/jbmr.0301212","article-title":"Fracture risk in monoclonal gammopathy of undetermined significance","volume":"19","author":"Melton","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.3816\/CLML.2010.n.053_bib23","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1365-2141.2006.06269.x","article-title":"Fracture risk in patients with monoclonal gammopathy of undetermined significance","volume":"135","author":"Gregersen","year":"2006","journal-title":"Br J Haematol"},{"key":"10.3816\/CLML.2010.n.053_bib24","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.beha.2007.08.004","article-title":"Genetic events in the pathogenesis of multiple myeloma","volume":"20","author":"Chng","year":"2007","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.3816\/CLML.2010.n.053_bib25","doi-asserted-by":"crossref","first-page":"5606","DOI":"10.1158\/1078-0432.CCR-09-1575","article-title":"Prevention of progression in monoclonal gammopathy of undetermined significance","volume":"15","author":"Rajkumar","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLML.2010.n.053_bib26","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/sj.leu.2404226","article-title":"Pathogen-associated molecular patterns are growth and survival factors for human myeloma cells through Toll-like receptors","volume":"20","author":"Jego","year":"2006","journal-title":"Leukemia"},{"key":"10.3816\/CLML.2010.n.053_bib27","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1038\/sj.leu.2404225","article-title":"Toll-like receptors mediate proliferation and survival of multiple myeloma cells","volume":"20","author":"Bohnhorst","year":"2006","journal-title":"Leukemia"},{"key":"10.3816\/CLML.2010.n.053_bib28","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/sj.leu.2404229","article-title":"Inflammation and multiple myeloma: the Toll connection","volume":"20","author":"Mantovani","year":"2006","journal-title":"Leukemia"},{"key":"10.3816\/CLML.2010.n.053_bib29","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1089\/jir.2006.26.83","article-title":"Identification of two groups of smoldering multiple myeloma patients who are either high or low producers of interleukin-1","volume":"26","author":"Xiong","year":"2006","journal-title":"J Interferon Cytokine Res"},{"key":"10.3816\/CLML.2010.n.053_bib30","doi-asserted-by":"crossref","first-page":"105","DOI":"10.4065\/84.2.105","article-title":"Targeting the pathogenic role of interleukin 1{beta} in the progression of smoldering\/indolent myeloma to active disease","volume":"84","author":"Dinarello","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"10.3816\/CLML.2010.n.053_bib31","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1182\/blood.V93.1.300","article-title":"Comparison of interleukin-1 beta expression by in situ hybridization in monoclonal gammopathy of undetermined significance and multiple myeloma","volume":"93","author":"Lacy","year":"1999","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.053_bib32","first-page":"5","article-title":"Immunophenotyping of plasma cells in multiple myeloma","volume":"113","author":"Mateo Manzanera","year":"2005","journal-title":"Methods Mol Med"},{"key":"10.3816\/CLML.2010.n.053_bib33","first-page":"837","article-title":"Differentiation of monoclonal gammopathy of undetermined significance and multiple myeloma using flow cytometric characteristics of plasma cells","volume":"86","author":"Sezer","year":"2001","journal-title":"Haematologica"},{"key":"10.3816\/CLML.2010.n.053_bib34","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","article-title":"New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells","volume":"110","author":"P\u00e9rez-Persona","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.053_bib35","doi-asserted-by":"crossref","first-page":"5369","DOI":"10.1158\/1078-0432.CCR-09-0040","article-title":"Gene expression profiling of bone marrow endothelial cells in patients with multiple myeloma","volume":"15","author":"Ria","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLML.2010.n.053_bib36","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.beha.2007.08.002","article-title":"The malignant clone and the bone-marrow environment","volume":"20","author":"Podar","year":"2007","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.3816\/CLML.2010.n.053_bib37","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/339058a0","article-title":"Induction of angiogenesis during the transition from hyperplasia to neoplasia","volume":"339","author":"Folkman","year":"1989","journal-title":"Nature"},{"key":"10.3816\/CLML.2010.n.053_bib38","first-page":"2210","article-title":"Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis","volume":"8","author":"Rajkumar","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLML.2010.n.053_bib39","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1158\/1078-0432.CCR-08-2310","article-title":"Dynamic contrast-enhanced magnetic resonance imaging identifies a subgroup of patients with asymptomatic monoclonal plasma cell disease and pathologic microcirculation","volume":"15","author":"Hillengass","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLML.2010.n.053_bib40","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","article-title":"MicroRNAs: genomics, biogenesis, mechanism, and function","volume":"116","author":"Bartel","year":"2004","journal-title":"Cell"},{"key":"10.3816\/CLML.2010.n.053_bib41","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/nrc1997","article-title":"MicroRNA signatures in human cancers","volume":"6","author":"Calin","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.3816\/CLML.2010.n.053_bib42","doi-asserted-by":"crossref","first-page":"12885","DOI":"10.1073\/pnas.0806202105","article-title":"MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis","volume":"105","author":"Pichiorri","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.3816\/CLML.2010.n.053_bib43","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3816\/CLM.2008.n.048","article-title":"Gene hypermethylation in multiple myeloma: lessons from a cancer pathway approach","volume":"8","author":"Chim","year":"2008","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.3816\/CLML.2010.n.053_bib44","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00277-009-0818-3","article-title":"DNA methylation analysis of tumor suppressor genes in monoclonal gammopathy of undetermined significance","volume":"89","author":"Stanganelli","year":"2010","journal-title":"Ann Hematol"},{"key":"10.3816\/CLML.2010.n.053_bib45","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1182\/blood-2006-09-049510","article-title":"Methylation and expression of the p16INK4A tumor suppressor gene in multiple myeloma","volume":"109","author":"Dib","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.053_bib46","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/sj.thj.6200084","article-title":"p16\/INK4a gene inactivation by hypermethylation is associated with aggressive variants of monoclonal gammopathies","volume":"2","author":"Mateos","year":"2001","journal-title":"Hematol J"},{"key":"10.3816\/CLML.2010.n.053_bib47","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1038\/sj.leu.2404304","article-title":"Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma","volume":"20","author":"Chiecchio","year":"2006","journal-title":"Leukemia"},{"key":"10.3816\/CLML.2010.n.053_bib48","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1182\/blood.V99.6.2185","article-title":"Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation","volume":"99","author":"Avet-Loiseau","year":"2002","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.053_bib49","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood.V100.4.1417.h81602001417_1417_1424","article-title":"Genomic abnormalities in monoclonal gammopathy of undetermined significance","volume":"100","author":"Fonseca","year":"2002","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.053_bib50","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1158\/0008-5472.CAN-03-2876","article-title":"Genetics and cytogenetics of multiple myeloma: a workshop report","volume":"64","author":"Fonseca","year":"2004","journal-title":"Cancer Res"},{"key":"10.3816\/CLML.2010.n.053_bib51","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1182\/blood-2004-03-0833","article-title":"Possible roles for activating RAS mutations in the MGUS to MM transition and in the intramedullary to extramedullary transition in some plasma cell tumors","volume":"105","author":"Rasmussen","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.053_bib52","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1038\/leu.2008.142","article-title":"Clinical and biological significance of RAS mutations in multiple myeloma","volume":"22","author":"Chng","year":"2008","journal-title":"Leukemia"},{"key":"10.3816\/CLML.2010.n.053_bib53","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.3324\/haematol.2008.004440","article-title":"Loss of 1p and rearrangement of MYC are associated with progression of smouldering myeloma to myeloma: sequential analysis of a single case","volume":"94","author":"Chiecchio","year":"2009","journal-title":"Haematologica"},{"key":"10.3816\/CLML.2010.n.053_bib54","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1182\/blood-2006-03-009910","article-title":"Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation","volume":"108","author":"Hanamura","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.053_bib55","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/j.1365-2141.2005.05673.x","article-title":"Comparative genomic hybridisation identifies two variants of smoldering multiple myeloma","volume":"130","author":"Rosi\u00f1ol","year":"2005","journal-title":"Br J Haematol"},{"key":"10.3816\/CLML.2010.n.053_bib56","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1182\/blood.V98.10.3082","article-title":"Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors","volume":"98","author":"Avet-Loiseau","year":"2001","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.053_bib57","doi-asserted-by":"crossref","first-page":"4197","DOI":"10.1200\/JCO.2008.19.1916","article-title":"Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma","volume":"27","author":"Anguiano","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.053_bib58","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","article-title":"The molecular classification of multiple myeloma","volume":"108","author":"Zhan","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.053_bib59","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood-2007-08-108357","article-title":"Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma","volume":"111","author":"Dispenzieri","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.053_bib60","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood-2005-03-1038","article-title":"Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.053_bib61","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1002\/ijc.24514","article-title":"Patterns of hematologic malignancies and solid tumors among 37,838 first-degree relatives of 13,896 patients with multiple myeloma in Sweden","volume":"125","author":"Kristinsson","year":"2009","journal-title":"Int J Cancer"},{"key":"10.3816\/CLML.2010.n.053_bib62","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood-2008-12-191676","article-title":"Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden","volume":"114","author":"Landgren","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.053_bib63","doi-asserted-by":"crossref","first-page":"6386","DOI":"10.1182\/blood-2009-02-203471","article-title":"Pesticide exposure and risk of monoclonal gammopathy of undetermined significance in the Agricultural Health Study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.053_bib64","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1182\/blood-2007-10-121285","article-title":"Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders","volume":"111","author":"Brown","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.053_bib65","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1182\/blood-2005-08-3449","article-title":"Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States","volume":"107","author":"Landgren","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.053_bib66","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/S0025-6196(11)61089-6","article-title":"Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana","volume":"82","author":"Landgren","year":"2007","journal-title":"Mayo Clin Proc"},{"key":"10.3816\/CLML.2010.n.053_bib67","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/j.1365-2141.2007.06873.x","article-title":"Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression","volume":"139","author":"Kyle","year":"2007","journal-title":"Br J Haematol"},{"key":"10.3816\/CLML.2010.n.053_bib68","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1046\/j.1365-2141.2003.04654.x","article-title":"Smoldering multiple myeloma: natural history and recognition of an evolving type","volume":"123","author":"Rosi\u00f1ol","year":"2003","journal-title":"Br J Haematol"},{"key":"10.3816\/CLML.2010.n.053_bib69","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1365-2141.2009.07929.x","article-title":"Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells","volume":"148","author":"P\u00e9rez-Persona","year":"2010","journal-title":"Br J Haematol"},{"key":"10.3816\/CLML.2010.n.053_bib70","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/jmri.10304","article-title":"Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging","volume":"17","author":"Choyke","year":"2003","journal-title":"J Magn Reson Imaging"},{"key":"10.3816\/CLML.2010.n.053_bib71","series-title":"Biochemistry","author":"Berg","year":"2002"},{"key":"10.3816\/CLML.2010.n.053_bib72","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1182\/blood-2002-08-2543","article-title":"Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341","volume":"101","author":"Hideshima","year":"2003","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.053_bib73","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1182\/blood-2006-04-016360","article-title":"Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma","volume":"109","author":"Jakob","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.053_bib74","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1600-0609.1993.tb00148.x","article-title":"Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I\u2013a randomized study. Myeloma Group of Western Sweden","volume":"50","author":"Hjorth","year":"1993","journal-title":"Eur J Haematol"},{"key":"10.3816\/CLML.2010.n.053_bib75","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma","volume":"341","author":"Singhal","year":"1999","journal-title":"N Engl J Med"},{"key":"10.3816\/CLML.2010.n.053_bib76","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1080\/10428190802005191","article-title":"Thalidomide and lenalidomide: Mechanism-based potential drug combinations","volume":"49","author":"Vallet","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.3816\/CLML.2010.n.053_bib77","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1182\/blood-2008-06-164228","article-title":"Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease","volume":"112","author":"Barlogie","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.053_bib78","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1600-0609.2009.01257.x","article-title":"Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma","volume":"82","author":"Stadtmauer","year":"2009","journal-title":"Eur J Haematol"},{"key":"10.3816\/CLML.2010.n.053_bib79","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","author":"Weber","year":"2007","journal-title":"N Engl J Med"},{"key":"10.3816\/CLML.2010.n.053_bib80","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N Engl J Med"},{"key":"10.3816\/CLML.2010.n.053_bib81","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.3816\/CLML.2010.n.053_bib82","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1756-8722-2-36","article-title":"Mechanism of action of lenalidomide in hematological malignancies","volume":"2","author":"Kotla","year":"2009","journal-title":"J Hematol Oncol"},{"key":"10.3816\/CLML.2010.n.053_bib83","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1182\/blood-2008-12-196238","article-title":"Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma","volume":"114","author":"Richardson","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.053_bib84","unstructured":"Clinicaltrials.gov [Web site]. Mateos MV, San Miguel J, Blad\u00e9 J, et al. QUIREDEX: Revlimid (lenalidomide) and dexamethasone (ReDex) treatment versus observation in patients with smoldering multiple myeloma with high risk of progression. ClinicalTrials.gov. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00480363. Accessed September 21, 2009"},{"key":"10.3816\/CLML.2010.n.053_bib85","doi-asserted-by":"crossref","unstructured":"Mateos MV, L\u00f3pez-Corral L, Hern\u00e1ndez MT, et al. Multicenter, randomized, open-label, phase III trial of lenalidomide-dexamethasone (Len\/Dex) vs. therapeutic abstention in smoldering multiple myeloma at high risk of progression to symptomatic MM: Results of the first interim analysis. Paper presented at: the 2009 American Society of Hematology Annual Meeting; December 5-8, 2009; New Orleans, LA. Abstract 614","DOI":"10.1182\/blood.V114.22.614.614"},{"key":"10.3816\/CLML.2010.n.053_bib86","doi-asserted-by":"crossref","first-page":"114","DOI":"10.4065\/84.2.114","article-title":"Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component","volume":"84","author":"Lust","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"10.3816\/CLML.2010.n.053_bib87","doi-asserted-by":"crossref","first-page":"5917","DOI":"10.1158\/1078-0432.CCR-08-2217","article-title":"The potential role of curcumin in patients with monoclonal gammopathy of undefined significance\u2013its effect on paraproteinemia and the urinary n-telopeptide of type i collagen bone turnover marker","volume":"15","author":"Golombick","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLML.2010.n.053_bib88","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.4049\/jimmunol.171.7.3863","article-title":"Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells","volume":"171","author":"Bharti","year":"2003","journal-title":"J Immunol"},{"key":"10.3816\/CLML.2010.n.053_bib89","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1182\/blood-2002-05-1320","article-title":"Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis","volume":"101","author":"Bharti","year":"2003","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.053_bib90","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.molonc.2008.09.006","article-title":"Curcumin in combination with bortezomib synergistically induced apoptosis in human multiple myeloma U266 cells","volume":"2","author":"Park","year":"2008","journal-title":"Mol Oncol"},{"key":"10.3816\/CLML.2010.n.053_bib91","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/cncr.23783","article-title":"A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma","volume":"113","author":"Musto","year":"2008","journal-title":"Cancer"},{"key":"10.3816\/CLML.2010.n.053_bib92","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3816\/CLM.2009.n.061","article-title":"Monoclonal gammopathy of undetermined significance: why identification of these patients and assessment of their skeletons is important","volume":"9","author":"Berenson","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.3816\/CLML.2010.n.053_bib93","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/leu.2008.291","article-title":"Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma","volume":"23","author":"Kyle","year":"2009","journal-title":"Leukemia"},{"key":"10.3816\/CLML.2010.n.053_bib94","unstructured":"Clinicaltrials.gov [Web site]. Celecoxib in preventing multiple myeloma in patients with monoclonal gammopathy or smoldering myeloma. ClinicalTrialsgov. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00099047. Accessed September 21, 2009"},{"key":"10.3816\/CLML.2010.n.053_bib95","unstructured":"Clinicaltrials.gov [Web site]. Omega 3 supplementation for the prevention of disease pogression in early stage chronic lymphocytic leukemia (ES-CLL), monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). ClinicalTrialsgov. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00899353. Accessed Septempber 21, 2009"},{"key":"10.3816\/CLML.2010.n.053_bib96","unstructured":"Clinicaltrials.gov [Web site]. Green tea extract in treating patients with monoclonal gammopathy of undetermined significance and\/or smoldering multiple myeloma. ClinicalTrialsgov. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00942422. Accessed September 21, 2009"},{"key":"10.3816\/CLML.2010.n.053_bib97","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1182\/blood-2009-07-230441","article-title":"Response: Multiple myeloma is universally preceded by a prolonged premalignant stage: novel clinical insights and future directions","volume":"114","author":"Landgren","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.053_bib98","doi-asserted-by":"crossref","first-page":"5008","DOI":"10.1200\/JCO.2009.23.6802","article-title":"Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma","volume":"27","author":"Lacy","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.053_bib99","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1182\/blood-2006-08-036947","article-title":"Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial","volume":"110","author":"Richardson","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.053_bib100","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N Engl J Med"},{"key":"10.3816\/CLML.2010.n.053_bib101","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1038\/leu.2009.173","article-title":"Proteasome inhibitors in the treatment of multiple myeloma","volume":"23","author":"Shah","year":"2009","journal-title":"Leukemia"},{"key":"10.3816\/CLML.2010.n.053_bib102","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1053\/j.seminhematol.2009.02.003","article-title":"Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib","volume":"46","author":"Mitsiades","year":"2009","journal-title":"Semin Hematol"},{"key":"10.3816\/CLML.2010.n.053_bib103","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1182\/blood-2009-06-224196","article-title":"A new pet for myeloma","volume":"114","author":"Dimopoulos","year":"2009","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011700301?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011700301?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:22:42Z","timestamp":1761870162000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265011700301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":103,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["S2152265011700301"],"URL":"https:\/\/doi.org\/10.3816\/clml.2010.n.053","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2010,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Smoldering (Asymptomatic) Multiple Myeloma: Revisiting the Clinical Dilemma and Looking Into the Future","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3816\/CLML.2010.n.053","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}